My apologies in advance, but most of my notes are in English, so I'll carry on in English.
Medicago uses a proprietary plant-based technology to develop a vaccine and therapeutics. Our vaccines are virus-like particles that mimic the shape and the appearance of the virus without being infectious or being able to cause any disease. Because they look like the virus, the human body recognizes them and raises an immune response.
Our proprietary technology is extremely versatile and positioned to support rapid response to pandemics. It has been developed to support the fight against pandemic threats and other emerging diseases.
As soon as the genetic sequence of a virus becomes available, Medicago can develop clinical grade material for a vaccine candidate in only a few weeks—an important feature for this pandemic as we see new coronavirus variants emerging. During the current COVID-19 pandemic, Medicago has reallocated nearly all its resources to develop a vaccine against COVID-19 and to accelerate its path to increasing Canada's domestic vaccine manufacturing capacity.
In addition to our COVID-19 program, Medicago is advancing a number of programs in public health, including a pandemic and a seasonal influenza vaccine currently under review by Health Canada.
With respect to our COVID-19 vaccine program, I'm pleased to share some highlights of our phase one trial that has been completed. The data have demonstrated that 100% of the study participants who received an adjuvanted formulation of the vaccine developed high levels of neutralizing antibody response and cell-mediated immune responses after the second dose.
Our phase two trial is approaching completion, and based on these results and regulatory approval, phase three will be launched in the upcoming weeks.
The phase three portion of the trial will enrol 30,000 subjects in more than 10 countries to make sure that we have diversity within our trial, and the results of this phase three study are expected this spring. We expect regulatory approval for the vaccine this summer, at the point where we will start delivering doses to the Canadian government.
The Government of Canada's support has been instrumental for Medicago's COVID-19 vaccine development program and the construction of our large-scale manufacturing facility. It will ensure availability of Canadian-made vaccines to the population and provide much needed domestic manufacturing capacity for vaccine, antibodies and other immunotherapies.
In addition, Canada's advance purchase order of our vaccine has allowed Medicago to reserve supply for Canada and provide the security needed to pivot resources from other programs and to focus on COVID-19 vaccine development and production.
I want to take this opportunity to thank government leaders and partners who have made this investment possible: the Public Health Agency of Canada; Innovation, Science and Economic Development Canada; Public Services and Procurement Canada; and the Government of Quebec. We are very grateful for your support and look forward to continuing to work with our government partners to protect Canadians from the current COVID-19 outbreak and future public health emergencies.
As we look to critical factors involved in preparing for pandemics, it might be useful to structure our response according to three major axes: time, economics and competencies. Pandemic response requires long-term planning given the many years required to develop a vaccine platform and build domestic infrastructure. Private-public partnership provides strong synergies. While Canada needs to secure technology and domestic production capacity, industry requires terms to ensure sustainability and to encourage private investment. Competencies are critical to ensure a domestic response chain from early research to clinical development, production and distribution.
Government—